full issue - Association of Biotechnology and Pharmacy

More documents

Recommendations

Info

Current Trends in Biotechnology and Pharmacy Vol. 5 (3) 1251-1272 July 2011, ISSN 0973-8916 (Print), 2230-7303 (Online) 1269 endothelin receptor antagonist: Implications for endothelin physiology. J Cardiovasc Pharmacol., 22: S377-S379. 42. Breu, V., Loffler, B.M. and Clozel, M. (1993). In vitro characterization of Ro 46- 2005, a novel synthetic non-peptide endothelin antagonist of ET A and ET B receptors. FEBS Lett., 334: 210-214. 43. Chong, C.C. (2009). Ambrisentan: A new, nonsulphonamide, selective endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. Current Treatment of Pulmonary Vascular Diseases, 1: 31-33. 44. Cao, S., Wang, L.C., Kwansa, H., Roman, R.J., Harder, D.R. and Koehler, R.C. (2009). Endothelin rather than 20-HETE contributes to loss of pial arteriolar dilation during focal cerebral ischemia with and without polymeric hemoglobin transfusion. Am J Physiol Regul Integr Comp Physiol., 296: R1412-1418. 45. Clozel, M. (2000). Endothelin receptor antagonists: current status and perspectives. J Cardiovasc Pharmacol., 35: S65-68. 46. Wellings, R.P., Warner, T.D., Thiemermann, C., Cristol, J.P., Corder, R. and Vane, J.R. (1993). Vasoconstriction in the rat kidney induced by endothelin-1 is blocked by PD 145065. J Cardiovasc Pharmacol., 22: S103-106. 47. Dobrowolski, L., Endlich, K., Sadowski, J. and Steinhausen, M. (1997). Cardiovascular and renal effects of endothelin receptor blockade with PD 145065 and interaction with urodilatin. Acta Physiol Scand., 159: 7-13. 48. Cardell, L.O., Uddman, R. and Edvinsson, L. (1993). A novel ET A -receptor antagonist, FR 139317, inhibits endothelin-induced contractions of guinea-pig pulmonary arteries, but not trachea. Br J Pharmacol., 108: 448-452. 49. Wu-Wong, J.R. (2002). S-0139 (Shionogi). Curr Opin Investig Drugs, 3: 1051-1056. 50. Opgenorth, T.J., Adler, A.L., Calzadilla, S.V., Chiou, W.J., Dayton, B.D., Dixon, D.B., Gehrke, L.J., Hernandez, L., Magnuson, S.R., Marsh, K.C., Novosad, E.I., Von Geldern, T.W., Wessale, J.L., Winn, M. and Wu-Wong, J.R. (1996). Pharmacological characterization of A- 127722: an orally active and highly potent ET A -selective receptor antagonist. J Pharmacol Exp Ther., 276: 473-481. 51. Krause, S.M., Walsh, T.F., Greenlee, W.J., Ranaei, R., Williams, D.L. and Kivlighn, S.D. (1997). Renal protection by a dual ET A /ET B endothelin antagonist, L-754,142, after aortic cross-clamping in the dog. J Am Soc Nephrol., 8: 1061-1071. 52. Enseleit, F., Luscher, T.F. and Ruschitzka, F. (2008). Darusentan: a new perspective for treatment of resistant hypertension Expert Opin Investig Drugs, 17: 1255- 1263. 53. Krum, H., Viskoper, R.J., Lacourciere, Y., Budde, M.and Charlon, V. (1998). The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med., 338: 784-790. 54. Dwyer, N. and Kilpatrick, D. (2011). Bosentan for the treatment of adult pulmonary hypertension. Future Cardiol., 7: 19-37. 55. Dingemanse, J. and van Giersbergen, P.L.M. (2004). Clinical pharmacology of Catherina Caballero-George
Current Trends in Biotechnology and Pharmacy Vol. 5 (3) 1251-1272 July 2011, ISSN 0973-8916 (Print), 2230-7303 (Online) Bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet, 43: 1089- 1115. 56. Iglarz, M., Binkert, C., Morrison, K., Fischli, W., Gatfield, J., Treiber, A., Weller, T., Bolli, M.H., Boss, C., Buchmann, S., Capeleto, B., Hess, P., Qiu, C. and Clozel, M. (2008). Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther., 327: 736-745. 57. Raja, S.G. (2010). Macitentan, a tissuetargeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs, 11: 1066-1073. 58. Miller, R.C., Pelton, J.T.and Huggins, J.P. (1993). Endothelins – from receptors to medicine. TiPS, 14: 54-60. 59. Doherty, A.M. (1992). Endothelin: a new challenge. Journal of Medicinal Chemistry, 35: 1493-1508. 60. Reily, M.D.and Dunbar, J.B. (1991). The conformation of endothelin-1 in aqueous solution. NMR-derived constrains combined with distance geometry and molecular mechanisms calculations. Biochem Biophys Res Commun., 178: 570- 577. 61. Takasaki, C., Aimoto, S., Tkayanagi, R., Ohashi, M. and Nawata, H. (1990). Structure-receptor binding relationships of sarafotoxin and endothelin in porcine cardiovascular tissues. Biochem Int., 21: 1059-1064. 62. Fukami, T., Nagase, T., Fujita, K., Hayama, T., Niiyama, K., Mase, T., Nakajima, S., Fukuroda, T., Saeki, T., Nishikibe, M., Ihara, M., Yano, M. and Ishikawa, K. Does nature has the cure for hypertension 1270 (1995). Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists. J Med Chem., 38: 4309-4324. 63. Ishikawa, K., Fukami, T., Nagase, T., Mase, T., Hayama, T., Niiyama, K., Fujita, K., Urakawa, Y., Kumagai, U., Fukuroda, T., Ihara, M. and Yano, M. (1992). Endothelin antagonistic peptide derivatives with high selectivity for ET A receptors. In Proceedings of the 22 nd European Peptide Symposium; ESCOM Science Publishers B.V.: Leiden, The Nederlands, 1992, pp 685-686. 64. Winn, M., von Geldern, T.W., Opgenorth, T.J., Jae, H., Tasker, A.S., Boyd, S.A., Kester, J.A., Mantei, R.A., Bal, R., Sorensen, B.K., Wu-Wong, J.R., Chiou, W.J., Dixon, D.B., Novosad, E.I., Hernandez, L. and Marsh, K.C. (1996). 2,4- Diarylpyrrolidine-3-carboxylic acidspotent ET A selective endothelin receptor antagonists. 1. Discovery of A-127722. J Med Chem., 39: 1039-1048. 65. Sakurawi, K., Yasuda, F., Tozyo, T., Nakamura, M., Sato, T., Kikuchi, J., Terui, Y., Ikenishi, Y., Iwata, T., Takahashi, K., Konoike, T., Mihara, S. and Fujimoto, M. (1996). Endothelin receptor antagonist triterpenoid, myriceric acid A, isolated from Myrica cerifera, and structure activity relationships of its derivatives. Chem Pharm Bull (Tokyo), 44: 343-351. 66. Timmermans, P.B. (1999). Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res., 22: 147-153. 67. Kojiri, K., Ihara, M., Nakajima, S., Kawamura, K., Funaishi, K., Yano, M. and Suda, H. (1991). Endothelin-binding inhibitors, BE-18257A and BE-18257B. I.
Page 3 and 4:
ISSN 0973-8916 Current Trends in Bi
Page 5 and 6:
Current Trends in Biotechnology and
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20: Current Trends in Biotechnology and
Page 61 and 62: β Current Trends in Biotechnology
Page 69: Current Trends in Biotechnology and
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175:
(December 7-9, 2011) Venue: Karunya
show all

full issue - Association of Biotechnology and Pharmacy

Create successful ePaper yourself

Delete template?

Save as template?